Tokyo Tape
Sign in
← Jmdc

Quarterly report · Q2

4483.TEDINET S100S9E5
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥13.7bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Revenue¥7.0bn2023-07-01 → 2023-09-30dCons.Revenue IFRS
Revenue¥27.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥12.1bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥6.3bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Operating income¥3.6bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Operating income¥1.1bn2023-07-01 → 2023-09-30dCons.Operating profit loss IFRS
Operating income¥2.2bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥1.1bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Profit before tax¥3.6bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.1bn2023-07-01 → 2023-09-30dCons.Profit loss before tax IFRS
Profit before tax¥5.9bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥2.2bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥1.1bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥2.7bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥621m2023-07-01 → 2023-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥4.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥678m2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥2.7bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Net income¥623m2023-07-01 → 2023-09-30dCons.Profit loss IFRS
Net income¥1.4bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥677m2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Total assets¥100.0bnat 2023-09-30Cons.Assets IFRS
Total assets¥98.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥112.1bnat 2022-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥31.3bnat 2023-09-30Cons.Liabilities IFRS
Total liabilities¥34.0bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥68.7bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥64.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥61.6bnat 2022-09-30Cons.Equity IFRS
Net assets / equity¥31.2bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥68.6bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥64.5bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥61.6bnat 2022-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥21.5bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥22.8bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥41.5bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.2bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥2.0bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥4.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥3.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥21.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥341m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥28.3bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥48.1bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥42.22023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥9.832023-07-01 → 2023-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥71.172022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥25.292022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥11.762022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥40.532023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥9.462023-07-01 → 2023-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥67.692022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥23.862022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥11.142022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio68.6%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio65.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio55.0%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 71
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥89m
Reconciling Itemsreconcilingrevenue2023-07-01 → 2023-09-30−¥13m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥89m
Reconciling Itemsreconcilingrevenue intersegment2023-07-01 → 2023-09-30−¥13m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥338m
Reconciling Itemsreconcilingsegment profit2023-07-01 → 2023-09-30−¥187m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-04-01 → 2023-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-07-01 → 2023-09-30¥292m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-04-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-07-01 → 2023-09-30¥292m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥50m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-04-01 → 2023-09-30¥133m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-07-01 → 2023-09-30¥45m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2023-04-01 → 2023-09-30¥9.8bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2023-07-01 → 2023-09-30¥5.3bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-04-01 → 2023-09-30¥9.8bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-07-01 → 2023-09-30¥5.3bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥38m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-07-01 → 2023-09-30¥13m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-04-01 → 2023-09-30¥2.5bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-07-01 → 2023-09-30¥1.2bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2023-04-01 → 2023-09-30¥2.7bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2023-07-01 → 2023-09-30¥1.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2023-04-01 → 2023-09-30¥2.7bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2023-07-01 → 2023-09-30¥1.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2023-04-01 → 2023-09-30¥1.0bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2023-07-01 → 2023-09-30¥566m
—segment totalrevenue2023-04-01 → 2023-09-30¥13.8bn
—segment totalrevenue2023-07-01 → 2023-09-30¥7.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥13.7bn
—segment totalrevenue external2023-07-01 → 2023-09-30¥7.0bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥89m
—segment totalrevenue intersegment2023-07-01 → 2023-09-30¥13m
—segment totalsegment profit2023-04-01 → 2023-09-30¥3.6bn
—segment totalsegment profit2023-07-01 → 2023-09-30¥1.8bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥126m
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥67m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥126m
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥67m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥189m
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥99m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-07-01 → 2022-09-30¥933m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.8bn
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-07-01 → 2022-09-30¥890m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥84m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥42m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-04-01 → 2022-09-30¥192m
jpcrp040300-q2r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-07-01 → 2022-09-30¥144m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue2022-07-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-04-01 → 2022-09-30¥7.9bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-07-01 → 2022-09-30¥4.1bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥42m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥24m
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-04-01 → 2022-09-30¥2.0bn
jpcrp040300-q2r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-07-01 → 2022-09-30¥903m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2022-04-01 → 2022-09-30¥2.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue2022-07-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2022-04-01 → 2022-09-30¥2.4bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentrevenue external2022-07-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2022-04-01 → 2022-09-30¥924m
jpcrp040300-q2r_E35308-000Tele Medicinereportable segmentsegment profit2022-07-01 → 2022-09-30¥485m
—segment totalrevenue2022-04-01 → 2022-09-30¥12.2bn
—segment totalrevenue2022-07-01 → 2022-09-30¥6.4bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥12.1bn
—segment totalrevenue external2022-07-01 → 2022-09-30¥6.3bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥126m
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥67m
—segment totalsegment profit2022-04-01 → 2022-09-30¥3.1bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥1.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 887
ItemContextValueUnit
Whether consolidated financial statements are preparedFilingDateInstanttrue
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstantCTE
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Current fiscal year start dateFilingDateInstant2023-04-01
Current period end dateFilingDateInstant2023-09-30
Type of current periodFilingDateInstantQ2
Current fiscal year end dateFilingDateInstant2024-03-31
Previous fiscal year start dateFilingDateInstant2022-04-01
Comparative period end dateFilingDateInstant2022-09-30
Previous fiscal year end dateFilingDateInstant2023-03-31
Next fiscal year start dateFilingDateInstant－
End date of quarterly or semi annual period of next fiscal yearFilingDateInstant－
Amendment flagFilingDateInstantfalse
Identification of document subject to amendmentFilingDateInstant－
Report amendment flagFilingDateInstantfalse
Xbrl amendment flagFilingDateInstantfalse
Business results of group (text)FilingDateInstantText · Plus
Description of business (text)FilingDateInstantText · Plus
Business risks (text)FilingDateInstantText · Plus
Management analysis of financial position operating results and cash flows (text)FilingDateInstantText · Plus
Critical contracts for operation (text)FilingDateInstantText · Plus
Total number of shares (text)FilingDateInstantText · Plus
Issued shares total number of shares etc (text)FilingDateInstantText · Plus
Class issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember
Original text (Japanese)普通株式
Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registeredFilingDateInstant_OrdinaryShareMember
Original text (Japanese)東京証券取引所(プライム市場)
Description issued shares total number of shares etcFilingDateInstant_OrdinaryShareMemberText · Plus
Details of employee share option program (text)FilingDateInstantText · Plus
Other information on share acquisition rights (text)FilingDateInstantText · Plus
Exercises etc of moving strike convertible bonds etc (text)FilingDateInstantText · Plus
Changes in number of issued shares stated capital etc (text)FilingDateInstantText · Plus
Major shareholders (text)FilingDateInstantText · Plus
Name major shareholdersCurrentQuarterInstant_No1MajorShareholdersMember
Original text (Japanese)オムロン株式会社
Address major shareholdersCurrentQuarterInstant_No1MajorShareholdersMember
Original text (Japanese)京都府京都市下京区塩小路通堀川東入南不動堂町801番地
Name major shareholdersCurrentQuarterInstant_No2MajorShareholdersMember
Original text (Japanese)ノーリツ鋼機株式会社
Address major shareholdersCurrentQuarterInstant_No2MajorShareholdersMember
Original text (Japanese)東京都港区麻布十番一丁目10番10号
Name major shareholdersCurrentQuarterInstant_No3MajorShareholdersMember
Original text (Japanese)日本マスタートラスト信託銀行株式会社（信託口）
Address major shareholdersCurrentQuarterInstant_No3MajorShareholdersMember
Original text (Japanese)東京都港区浜松町二丁目11番３号
Name major shareholdersCurrentQuarterInstant_No4MajorShareholdersMember
Original text (Japanese)松島　陽介
Address major shareholdersCurrentQuarterInstant_No4MajorShareholdersMember
Original text (Japanese)東京都世田谷区
Name major shareholdersCurrentQuarterInstant_No5MajorShareholdersMemberMORGAN STANLEY & CO. INTERNATIONAL PLC
Address major shareholdersCurrentQuarterInstant_No5MajorShareholdersMember25 CABOT SQUARE, CANARY WHARF, LONDON E14 4QA, U.K.
Name major shareholdersCurrentQuarterInstant_No6MajorShareholdersMember
Original text (Japanese)山元　雄太
Address major shareholdersCurrentQuarterInstant_No6MajorShareholdersMember
Original text (Japanese)東京都港区
Name major shareholdersCurrentQuarterInstant_No7MajorShareholdersMember
Original text (Japanese)株式会社日本カストディ銀行（信託口）
Address major shareholdersCurrentQuarterInstant_No7MajorShareholdersMember
Original text (Japanese)東京都中央区晴海一丁目８番12号
Name major shareholdersCurrentQuarterInstant_No8MajorShareholdersMemberJP JPMSE LUX RE CITIGROUP GLOBAL MARKETS L EQ CO
Address major shareholdersCurrentQuarterInstant_No8MajorShareholdersMemberText · Plus
Name major shareholdersCurrentQuarterInstant_No9MajorShareholdersMemberJP JPMSE LUX RE BARCLAYS CAPITAL SEC LTD EQ CO
Address major shareholdersCurrentQuarterInstant_No9MajorShareholdersMemberText · Plus
Name major shareholdersCurrentQuarterInstant_No10MajorShareholdersMemberJP JPMSE LUX RE UBS AG LONDON BRANCH EQ CO

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-07-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2023-07-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass